Medherant had a very successful trip to BioEurope in Munich on the 2-4 November. Whilst there we gave a short pitch in the Emerging Technologies Forum to introduce the Medherant technology platform and to showcase our early results in the development of the world's first drug-in-adhesive ibuprofen patch, improved existing lidocaine, nicotine and methyl salicylate patches and some of our extensive POC data for over 20 transdermal and topical drugs currently formulated in either patches, gels or creams.
We had over 30 very encouraging partnering meetings with companies who could be potential investors or development partners – meeting with global leaders in the fields of transdermal delivery and consumer health and a number of European and global VC’s with interest in taking part in our upcoming Series A financing round.
A great success for us which could lead to some very interesting partnerships in the future.
Download our presentation from this meeting.